Shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI - Get Free Report) gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $13.92, but opened at $15.25. Lumexa Imaging shares last traded at $15.9720, with a volume of 92,913 shares changing hands.
The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.07 by $0.19. The firm had revenue of $271.97 million for the quarter.
Top Lumexa Imaging Stories
These are some of the LMRI stories that stood out recently:
- Positive Sentiment: Revenue increased 5% year over year to about $272 million, gross profit rose 16.9%, and operating cash flow climbed to $34.8 million from a year earlier. These trends point to improved revenue and cash generation. Q3 financial details
- Neutral Sentiment: LMRI also provided guidance, but the supplied reports do not specify its details, limiting assessment of the outlook. Guidance report
- Negative Sentiment: Results were not uniformly strong: one financial summary lists diluted EPS of $0.07 against a $0.19 estimate, revenue slightly below its $275.3 million estimate, and operating profit down 7.3% year over year. The differing EPS figures across reports make the earnings comparison less clear. Financial summary
Wall Street Analyst Weigh In
Several brokerages recently commented on LMRI. Weiss Ratings reissued a "sell (d)" rating on shares of Lumexa Imaging in a report on Tuesday, September 22nd. Truist Financial began coverage on Lumexa Imaging in a research note on Monday, October 5th. They set a "buy" rating and a $18.00 price target for the company. UBS Group reiterated a "strong-buy" rating on shares of Lumexa Imaging in a research report on Monday, September 28th. Barclays boosted their price objective on Lumexa Imaging from $9.00 to $13.00 and gave the stock an "overweight" rating in a research note on Friday, August 28th. Finally, Raymond James Financial set a $17.00 price objective on Lumexa Imaging in a report on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $16.40.
Check Out Our Latest Analysis on LMRI
Institutional Trading of Lumexa Imaging
Several institutional investors have recently made changes to their positions in the stock. Strs Ohio acquired a new position in Lumexa Imaging in the 1st quarter worth about $38,000. State of Alaska Department of Revenue bought a new stake in shares of Lumexa Imaging in the 3rd quarter valued at approximately $46,000. PNC Financial Services Group Inc. bought a new stake in shares of Lumexa Imaging in the 1st quarter valued at approximately $63,000. State of Wyoming acquired a new position in Lumexa Imaging in the first quarter worth approximately $91,000. Finally, AXQ Capital LP acquired a new position in Lumexa Imaging in the second quarter worth approximately $128,000.
Lumexa Imaging Stock Performance
The stock has a market cap of $1.53 billion and a P/E ratio of -32.41. The firm's 50-day moving average is $11.24 and its two-hundred day moving average is $11.07. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40.
Lumexa Imaging Company Profile
(
Get Free Report)
Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lumexa Imaging, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lumexa Imaging wasn't on the list.
While Lumexa Imaging currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.